Overview

Dexpramipexole SAD/MAD Study

Status:
Completed

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Knopp Biosciences

Treatments:

Pramipexole